Detalhe da pesquisa
1.
Backfilling cohorts in phase I dose-escalation studies.
Clin Trials
; 20(3): 261-268, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36951478
2.
Dose finding studies for therapies with late-onset toxicities: A comparison study of designs.
Stat Med
; 41(30): 5767-5788, 2022 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36250912
3.
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(10): 1454-1466, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31405822
4.
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Clin Cancer Res
; 28(7): 1285-1293, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35046056
5.
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Clin Cancer Res
; 27(23): 6366-6375, 2021 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34518310
6.
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Immunotherapy
; 13(2): 125-141, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33172323
7.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31835495
8.
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
BMJ
; 383: e076386, 2023 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37863491
9.
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
BMJ
; 383: e076387, 2023 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37863501
10.
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Clin Cancer Res
; 28(13): 2969, 2022 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35775194
11.
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Cancer Chemother Pharmacol
; 76(4): 777-84, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26281907
12.
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Clin Cancer Res
; 18(9): 2658-67, 2012 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22421192